Savara Inc Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
Savara Inc (SVRA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $543.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-06.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2017-03-06
- Savara Inc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2016 was $543.00K, a 8.59% decline from fiscal 2015.
- Savara Inc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2015 was $594.00K, a 113.67% increase from fiscal 2014.
- Savara Inc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2014 was $278.00K, a 34.30% increase from fiscal 2013.
- Savara Inc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2013 was $207.00K, a 0.98% increase from fiscal 2012.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2016-12-31 | $543.00K 10-K · filed 2017-03-06 |
| 2015-12-31 | $594.00K 10-K · filed 2017-03-06 |
| 2014-12-31 | $278.00K 10-K · filed 2017-03-06 |
| 2013-12-31 | $207.00K 10-K · filed 2015-03-24 |
| 2012-12-31 | $205.00K 10-K · filed 2014-03-26 |
| 2011-12-31 | $386.00K 10-K · filed 2013-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |